An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.

scientific article published on 22 September 2011

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00280-011-1733-6
P698PubMed publication ID21938545

P50authorChandra BelaniQ40073451
P2093author name stringPaul Haluska
Ramesh K Ramanathan
S Gail Eckhardt
Stephen Leong
Karsten Witt
Cindy L O'Bryant
Suresh Ramalingam
Ramesh Boinpally
Lee Rosen
Balaji Venugopal
Jeffry Evans
Amy Franke
P2860cites workErlotinib in previously treated non-small-cell lung cancerQ29547546
EGFR antagonists in cancer treatmentQ29616740
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupQ29619344
Phase II study of erlotinib in patients with advanced biliary cancerQ33997258
Transection of the oesophagus for bleeding oesophageal varicesQ34211834
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.Q34436986
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimenQ34451318
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancerQ34560933
Clinical pharmacokinetics of tyrosine kinase inhibitorsQ34611569
Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancerQ35956595
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokersQ37155636
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancerQ40489484
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesQ43658492
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.Q45970694
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicityQ46726161
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinibQ46809344
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.Q51779657
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.Q51936030
P433issue3
P921main subjecterlotinibQ418369
P304page(s)605-612
P577publication date2011-09-22
P1433published inCancer Chemotherapy and PharmacologyQ326137
P1476titleAn open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
P478volume69

Reverse relations

cites work (P2860)
Q28068579Cancer and liver cirrhosis: implications on prognosis and management
Q26861560Hepatotoxicity Secondary to Chemotherapy
Q35927299Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
Q54267525Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Q49909297Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
Q52666663Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation.

Search more.